Researchers identified HERC4 as a critical molecular switch converting TNF survival signaling into cell death. The finding links TNF pathway biology to druggable targets and opens an oral-therapy route for chronic inflammatory diseases, offering a mechanism-focused strategy rather than broad cytokine blockade.